ABBV · AbbVie Inc.
AI read · Good for ABBV
The AI's read
AbbVie reported Phase 3 LUNA results for atogepant in menstrual migraine. The drug reduced perimenstrual migraine days by 0.80 days versus placebo and hit all eight ranked secondary endpoints.
AbbVie's medicine cuts down the number of days women suffer from menstrual migraines.
Good for ABBV
AbbVie reported Phase 3 LUNA results showing 0.80 fewer perimenstrual migraine days versus placebo and statistical significance across 8 secondary endpoints. This supports commercial prospects for atogepant globally.
Get alerts for ABBV
Follow AbbVie Inc. (ABBV) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ABBVFree on the App Store and Google Play, or on the web.